Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial (NCT04881825)
A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Completing the EASE SBS 2 Trial
🩺 Plain-English Summary (8th-Grade Level)
This trial is an extension trial to EASE SBS 2. The study looks at whether glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment. Participants in this trial will receive glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.) for approximately 2 years.
Who can join: Review the eligibility criteria below.
Location: Georgetown University Medical Center — Washington D.C., District of Columbia
Age range: 18 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Georgetown University Medical Center — Washington D.C., District of Columbia
- Mayo Clinic College of Medicin — Rochester, Minnesota
- University of Nebraska Medical Center — Omaha, Nebraska
- Vanderbilt University Medical Center, Nashville — Nashville, Tennessee
- Universitair Ziekenhuis Leuven — Leuven,
- Rigshospitalet — Copenhagen,
- Hôpital Beaujon — Clichy,
- Centre Hospitalier Lyon-Sud — Pierre-Bénite,
- Charité - Universitätsmedizin Berlin — Berlin,
- Universitätsklinikum Bonn — Bonn,
- Universitätsklinikum Frankfurt — Frankfurt,
- Asklepios Kliniken Hamburg GmbH — Hamburg,
- Universitätsmedizin Rostock — Rostock,
- UMC Radboud Nijmegen — Nijmegen,
- Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi — Lodz,
- Szpital Skawina sp. z o.o. im. Stanley Dudricka — Skawina,
- St Mark's Hospital — Harrow,
- UCLH Foundation NHS Trust — London,
- Norfolk and Norwich University Hospitals — Norwich,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Short Bowel Syndrome
- Registry for Participants With Short Bowel Syndrome — Lexington, Massachusetts
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS — Washington D.C., District of Columbia
- Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome — Cleveland, Ohio
- Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. — Los Angeles, California
- A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome — Palo Alto, California
Explore by condition: All Short Bowel Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.